Skip Navigation



Annals of Oncology Advance Access published online on July 17, 2008
Annals of Oncology, doi:10.1093/annonc/mdn424
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/12/2012    most recent
mdn424v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Largillier, R.
Right arrow Articles by Chamorey, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Largillier, R.
Right arrow Articles by Chamorey, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Prognostic factors in 1038 women with metastatic breast cancer

R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, C. Balu-Maestro, P. Y. Marcy, I. Raoust, M. Lallement and E. Chamorey*

Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France

* Correspondence to: Dr E. Chamorey, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 NICE Cedex 2, France. Tel: +33-4-9203-1529; Fax: +33-4-9381-7131; E-mail: emmanuel.chamorey{at}nice.fnclcc.fr

Background: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with MBC represent a heterogeneous group whose prognosis and outcome may be dependent on host factors. The purpose of the present study was dual: first, to draw up a list of factors easily available in everyday clinical practice requiring no sophisticated or costly methods and second, to provide results from a large cohort of women who underwent diagnostic and treatment at a single institution.

Patients and methods: From 1975 to 2005, a total of 1038 women with MBC during their follow-up were included in this retrospective analysis. Patients were subsequently assigned to five groups according to the period of metastatic diagnosis.

Results: It is shown that age at initial diagnosis, hormonal receptor status and site of metastasis are the most relevant prognostic factors for predicting survival from the time of metastastic occurrence. It is also shown that a metastasis-free interval is an easily and immediately available multifactorial prognostic index reflecting the multiparametric variability of the disease.

Conclusion: These fundamental observations may assist physicians in evaluating the survival potential of patients and in directing them toward the appropriate therapeutic decision.

MBC, prognostic factors, survival

Received for publication April 12, 2008. Revision received June 17, 2008. Accepted for publication June 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
O. Dizdar, S. Aksoy, and K. Altundag
Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?
Ann. Onc., January 1, 2009; 20(1): 189 - 189.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Chamorey, J. Barriere, J. M. Ferrero, and R. Largillier
Reply to Adjuvant chemotherapy and prognosis in patients with breast cancer
Ann. Onc., January 1, 2009; 20(1): 193 - 194.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Kilickap and C. Arslan
Adjuvant chemotherapy and prognosis in patients with breast cancer
Ann. Onc., January 1, 2009; 20(1): 192 - 193.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Chamorey, J. Barriere, J. M. Ferrero, and R. Largillier
Reply to Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?
Ann. Onc., January 1, 2009; 20(1): 189 - 190.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.